Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is commonly used for cancer patients following myelosuppressive cytotoxic chemotherapy, and it decreases the risk of potentially fatal infections and hospitalisation associated with febrile neutropenia (FN) and ensures that the dose intensity of chemotherapy improves the overall survival (OS) [6]. This evidence concerns the gene CSF3 and cancer.